Nausea rates were not higher with any treatment compared with placebo.

Abacor showed a rapid onset of effect, as compared with placebo.

It was compared with placebo in those late-stage studies, rather than to Enbrel.

Minocycline was well tolerated with significantly fewer headaches and constipation compared with placebo.

Caplacizumab was associated with an increased tendency toward bleeding, as compared with placebo.

Under paroxetine, ratings of subjective sexual dysfunction increased compared with placebo or bupropion.

Compared with placebo, quetiapine improved sleep quality, increased caloric intake and decreased weight loss.

Orteronel plus prednisone was associated with increased toxic effects compared with placebo plus prednisone.

There were no significant improvements while on atomoxetine compared with placebo on primary outcomes.

Responses to rosiglitazone were compared with placebo using paired t-tests.

Conclusion: Treatment with selexipag did not reduce the number of RP attacks compared with placebo.

Results: The oxygen cost at submaximal exercise was reduced after nitrate supplementation compared with placebo.

Previous trials of cardiovascular FDCs have assessed short-term effects compared with placebo or no treatment.

During intermittent exercise, maximum norepinephrine levels were significantly reduced by beta blockade compared with placebo.

Randomized controlled clinical trials have shown that bupropion SR doubles abstinence rates compared with placebo.

Compared with placebo, indomethacin improved postprandial gallbladder emptying in all 7 patients with gallstone disease.